SCHEMBL23015751

SCHEMBL23015751

CC(C)c1ccnc(NC(=O)c2cccnc2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.64
RAB9A P51151 5/20 0.64
SMN1; SMN2 Q16637 5/20 0.64
TP53 P04637 2/20 0.64
PRKAB2 O43741 1/20 0.60
PRKAG1 P54619 1/20 0.60
PRKAA2 P54646 1/20 0.60
PRKAA1 Q13131 1/20 0.60
PRKAG3 Q9UGI9 1/20 0.60
PRKAG2 Q9UGJ0 1/20 0.60
PRKAB1 Q9Y478 1/20 0.60
MAPK8 P45983 1/20 0.58
MAPK10 P53779 1/20 0.58
MAPKAPK2 P49137 1/20 0.58
ALDH1A1 P00352 5/20 0.54
GAA P10253 3/20 0.54
AGTR1 P30556 1/20 0.54
HTT P42858 1/20 0.53
CYP2C19 P33261 1/20 0.53
TDP1 Q9NUW8 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16654040 0.86 NPC1 (0.60) NPC1RAB9AMAPKAPK2ALDH1A1GAA
SCHEMBL23015669 0.83 RAB9A (0.62) NPC1RAB9ASMN1; SMN2TP53PRKAB2
SCHEMBL23015752 0.82 RAB9A (0.67) NPC1RAB9ASMN1; SMN2PRKAB2PRKAG1
SCHEMBL23015834 0.81 PRKAB2 (0.59) NPC1RAB9ASMN1; SMN2TP53PRKAB2
SCHEMBL20016542 0.81 MEN1 (0.58) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL6174621 0.80 RAB9A (0.73) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL21348760 0.80 KMT2A (0.54) NPC1RAB9ASMN1; SMN2TP53ALDH1A1
SCHEMBL29899004 0.80 MAPK8 (0.62) NPC1RAB9ASMN1; SMN2PRKAB2PRKAG1
SCHEMBL23410523 0.80 MAPK8 (0.62) NPC1RAB9ASMN1; SMN2PRKAB2PRKAG1
SCHEMBL23446461 0.80 MAPK8 (0.62) NPC1RAB9ASMN1; SMN2PRKAB2PRKAG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors PHARMASUM THERAPEUTICS AS (NO) 2021-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10927106-B2 Benzothiazole derivatives as DYRK1 inhibitors DYRK1A, DYRK1B, PDK2 NPC1 2121/4885RAB9A 1200/4885SMN1; SMN2 2813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.